TRANSFORMING THE LIVES OF INDIVIDUALS
AND FAMILIES FIGHTING HEART DISEASE
Tenaya Therapeutics is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.
Tenaya is founded by world-leading scientists from the Gladstone Institute’s Cardiovascular Division and the University of Texas Southwestern Medical Center.
Tenaya seeks to address heart disease through three distinct and multi-modality platforms: a Regeneration Platform, a Gene Therapy Platform, and a Precision Medicine Platform.
LATEST NEWS
Tenaya Therapeutics Closes $92 Million Series B Financing
– Proceeds advance heart disease projects from three product platforms toward the clinic –
SOUTH SAN FRANCISCO, Calif., October 3, 2019 – Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease, today announced the successful completion of a $92 million Series B financing.
Read MoreTenaya Therapeutics Strengthens Leadership Team with Appointment of Two Biopharmaceutical Industry Veterans
–Company Expands Scientific Advisory Board with Addition of Experts in Cardiovascular Genetics, Gene Therapy and Molecular Biology–
South San Francisco, Calif. – March 13, 2019 – Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, M.D., Ph.D., as Chief Medical Officer, and Kee-Hong Kim, Ph.D., as Senior Vice President of Manufacturing and Technical Operations.
Read MoreTenaya Therapeutics appoints Faraz Ali as Chief Executive Officer
South San Francisco, CA – July 30, 2018 – Tenaya Therapeutics, a preclinical-stage biotechnology company focused on discovery and development of novel therapies for heart failure, announced the appointment of Faraz Ali as Chief Executive Officer.“We are thrilled to bring Faraz on board as the new CEO,” said David Goeddel, Ph.D., Managing Partner at The Column Group and Chairman of the Board of Directors at Tenaya. “The Board felt his strategic vision, track record of relevant operational experience, and commitment to building a leading heart failure company over the long-term make him an outstanding choice for Tenaya.”
Read MoreJoin Our Team
Are you ambitious, driven, energized by scientific innovation and committed to making a difference for patients suffering from heart disease? Do you value a culture grounded in science and teamwork? We are looking for experienced biopharmaceutical professionals and scientists to join the Tenaya team who want to help us advance our mission of using cutting-edge science and precision medicine to develop innovative therapies to transform the treatment of heart disease.